In a recent press release, Pfizer Incorporated said its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.
The company said a two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose.
“As the global health community works to increase the number of vaccinated people around the world, these additional data provide further confidence in our vaccine’s safety and effectiveness profile in adolescents. This is especially important as we see rates of COVID-19 climbing in this age group in some regions, while vaccine uptake has slowed,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “We look forward to sharing these data with the FDA and other regulators.”
“These are the first and only disclosed longer-term data demonstrating the safety and efficacy of a COVID-19 vaccine in individuals 12 through 15 years of age,” said Ugur Sahin, CEO and Co-founder of BioNTech.”
He said further, “The growing body of data we have compiled from clinical trials and real-world surveillance to date strengthen the base of evidence supporting the strong efficacy and favorable safety profile of our COVID-19 vaccine across adolescent and adult populations.”
The release noted that the long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.
Pfizer and BioNTech will seek clearance for a 30 microgram dose of the vaccine for those aged 12 and older.
Readers Bureau, Contributor
Edited by Jesus Chan
Do you want to add feedback to this story? Please add a comment in the box below or send an email to firstname.lastname@example.org, Call us at 201-500-7715